Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis

Background & Aims: Treatment with non-selective beta-blockers (NSBBs) reduces the risk of ascites, which is the most common decompensating event in cirrhosis. This study aimed to assess the ability of a serum microRNA (miRNA) signature to predict ascites formation and the hemodynamic respons...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Ana Garcia Garcia de Paredes, Càndid Villanueva, Carolina Blanco, Joan Genescà, Nicolo Manicardi, Juan Carlos Garcia-Pagan, Jose Luis Calleja, Carlos Aracil, Rosa M. Morillas, Maria Poca, Beatriz Peñas, Salvador Augustin, Juan G. Abraldes, Eldimar Alvarado, Félix Royo, Maria Laura Garcia-Bermejo, Juan Manuel Falcon-Perez, Rafael Bañares, Jaime Bosch, Jordi Gracia-Sancho, Agustin Albillos
Format:	article
Langue:	EN
Publié:	Elsevier 2021
Sujets:	Ascites beta-blockers cirrhosis microRNA portal hypertension Diseases of the digestive system. Gastroenterology RC799-869
Accès en ligne:	https://doaj.org/article/59ab79c9a0de4e2da9fed5699a961c6b
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Soyez le premier à ajouter un commentaire!

Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis

Documents similaires